See more : MKVENTURES CAPITAL LIMITED (MKVENTURES.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Cardio Diagnostics Holdings, Inc. (CDIO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cardio Diagnostics Holdings, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Guangdong Hec Technologyholding Co., Ltd (600673.SS) Income Statement Analysis – Financial Results
- SH Group (Holdings) Limited (1637.HK) Income Statement Analysis – Financial Results
- Talenom Oyj (TNOM.HE) Income Statement Analysis – Financial Results
- Lån & Spar Invest – Globale Aktier Basis (LSIGAB.CO) Income Statement Analysis – Financial Results
- DUET Acquisition Corp. (DUETU) Income Statement Analysis – Financial Results
Cardio Diagnostics Holdings, Inc. (CDIO)
About Cardio Diagnostics Holdings, Inc.
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease risk assessment test. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is based in Chicago, Illinois.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 17.07K | 950.00 | 901.00 | 0.00 |
| Cost of Revenue | 0.00 | 16.00K | 0.00 | 0.00 |
| Gross Profit | 17.07K | -15.05K | 901.00 | 0.00 |
| Gross Profit Ratio | 100.00% | -1,584.21% | 100.00% | 0.00% |
| Research & Development | 145.18K | 40.45K | 31.47K | 1.50K |
| General & Administrative | 6.94M | 4.40M | 470.56K | 591.52K |
| Selling & Marketing | 158.51K | 92.70K | 103.32K | 5.48K |
| SG&A | 7.10M | 4.49M | 573.88K | 597.00K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 4.00K |
| Operating Expenses | 7.26M | 4.55M | 621.35K | 609.16K |
| Cost & Expenses | 7.26M | 4.55M | 621.35K | 609.16K |
| Interest Income | 1.07K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 6.74M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 111.62K | 16.00K | 16.00K | 10.67K |
| EBITDA | -1.53M | -4.64M | -604.45K | -598.50K |
| EBITDA Ratio | -8,966.90% | -465,254.42% | -67,086.35% | 0.00% |
| Operating Income | -7.24M | -4.55M | -620.45K | -609.16K |
| Operating Income Ratio | -42,440.43% | -478,784.32% | -68,862.15% | 0.00% |
| Total Other Income/Expenses | -1.13M | -112.53K | 0.00 | 4.00K |
| Income Before Tax | -8.38M | -4.66M | -620.45K | -605.16K |
| Income Before Tax Ratio | -49,087.81% | -490,630.00% | -68,862.15% | 0.00% |
| Income Tax Expense | 0.00 | 112.53K | 2.00 | 0.00 |
| Net Income | -8.38M | -4.66M | -620.45K | -605.16K |
| Net Income Ratio | -49,087.81% | -490,630.00% | -68,862.15% | 0.00% |
| EPS | -0.66 | -1.51 | -0.53 | -0.06 |
| EPS Diluted | -0.66 | -1.51 | -0.53 | -0.06 |
| Weighted Avg Shares Out | 12.69M | 3.09M | 1.16M | 9.51M |
| Weighted Avg Shares Out (Dil) | 12.69M | 3.09M | 1.16M | 9.51M |
Cardio Diagnostics Holdings, Inc Launches New Lab and Fulfillment Center, Paving Way for Expanded Testing Capacity, Reduced Costs, Reduced Turnaround Time and Improved Margins
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics today announced the launch of the Company's new integrated facility in Iowa City, Iowa.
Cardio Diagnostics Publishes Novel and Scalable Pathways to Enhance Global Coronary Heart Disease Care through Precision Epigenetics in Epigenomics
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics and Dr. Damon Broyles published an article on scalable pathways that leverage precision epigenetics to revolutionize CHD.
Cardio Diagnostics Holdings, Inc Partners with Ascension Borgess Hospital's Heart Attack Prevention Clinic on Coronary Artery Disease Study
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics announces its AI-driven Epi+Gen CHD and PrecisionCHD tests will be leveraged in a research study led by Dr. Vishal Gupta.
Cardio Diagnostics Holdings, Inc to Participate in Upcoming Investor Conferences
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics announced that Meesha Dogan, Ph.D., CEO of Cardio Diagnostics, will present at two upcoming investor conferences.
Cardio Diagnostics Partners With FRSTeam of East Kansas and West Missouri to Host First Onsite Heart Disease Fair in Kansas Using Epigenetic-Genetic Technologies
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics announced the successful completion of an employer-sponsored heart disease fair in Kansas, United States.
Cardio Diagnostics Holdings, Inc Announces Expansion of IP Portfolio in Australia with Notice of Allowance of Patent Application
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics today announced the expansion of its IP portfolio in Australia with Notice of Allowance of Patent Application.
Cardio Diagnostics Holdings, Inc’s Actionable Clinical IntelligenceTM (ACI) Platform Offers New Epigenetic and Genetic Insights to Inform Coronary Heart Disease Management
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), an artificial intelligence-powered precision cardiovascular medicine company, announced the introduction of the Actionable Clinical IntelligenceTM (ACI) platform to expand the information available to clinicians prescribing the Epi+Gen CHD and PrecisionCHD laboratory developed tests...
Transforming Heart Disease Prevention for Self-Insured Employers in Oklahoma, Missouri, Kansas, and Arkansas: A Strategic Alliance between Connect Clinic and Cardio Diagnostics
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), a precision cardiovascular medicine company, today announced a partnership with Connect Clinic to help MidWest/South Central self-insured employers build access to heart disease initiatives. These states lack ready access to precision heart disease...
Cardio Diagnostics Holdings, Inc Unveils The CardioInnovate360TM BioPharma Research System
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), a precision cardiovascular medicine company, today announced the availability of its CardioInnovate360TM research-use-only (RUO) solution for biopharmaceutical companies that have and/or are developing therapeutics for cardiovascular disease (CVD) conditions or associated co-morbidities. According...
Juniper Research Awards Cardio Diagnostics Holdings, Inc Future Digital Award for Best Digital Diagnostics Solution
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), a precision cardiovascular medicine company, today announced its PrecisionCHD™ test received Juniper Research’s Future Digital Award for the “Best Digital Diagnostics Solution.” Juniper Research’s Future Digital Awards for Digital Health Innovation recognizes tech...
Source: https://incomestatements.info
Category: Stock Reports